As an alternative algorithm, NTRK testing could be performed after histological confirmation of NSCLC and, in the case of adenocarcinoma, immunohistochemical exclusion of ALK or ROS1 alterations. This evidence concerns the gene ALK and non-small cell lung carcinoma.